The impact of stigma on people with opioid use disorder, opioid treatment, and policy

A Cheetham, L Picco, A Barnett… - Substance abuse and …, 2022 - Taylor & Francis
Illicit drug use disorders are the most stigmatised health conditions worldwide, and stigma
acts as a meaningful barrier to treatment entry and treatment provision. In the context of …

[HTML][HTML] Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system

BK Madras, NJ Ahmad, J Wen, JS Sharfstein - NAM perspectives, 2020 - ncbi.nlm.nih.gov
Even though evidence-based treatment for opioid use disorders (OUD) is effective, almost
four in five Americans with OUD do not receive any form of treatment. The gap in access to …

Does naloxone provision lead to increased substance use? A systematic review to assess if there is evidence of a 'moral hazard'associated with naloxone supply

WC Tse, F Djordjevic, V Borja, L Picco, T Lam… - International Journal of …, 2022 - Elsevier
Background Take home naloxone (THN) programs have been rapidly upscaled in response
to increasing opioid-related mortality. One often cited concern is that naloxone provision …

What is known about community pharmacy-based take-home naloxone programs and program interventions? A scoping review

A Cid, G Daskalakis, K Grindrod, MA Beazely - Pharmacy, 2021 - mdpi.com
A variety of new sources describing community pharmacy-based take-home naloxone (THN)
programs have emerged recently in the literature. There is a need to define the types of take …

How do patient, pharmacist and medication characteristics and prescription drug monitoring program alerts influence pharmacists' decisions to dispense opioids? A …

L Picco, P Sanfilippo, T Xia, T Lam, S Nielsen - International Journal of Drug …, 2022 - Elsevier
Background Prescription drug monitoring programs (PDMP) are electronic databases that
track the prescribing and dispensing of high-risk medicines such as opioids. They have the …

[HTML][HTML] A qualitative study of a publicly funded pharmacy-dispensed naloxone program

T Antoniou, C Pritlove, D Shearer, D Martins… - International Journal of …, 2021 - Elsevier
Aims To characterize the experiences of individuals accessing pharmacy-based naloxone
and relate these experiences to the risk environments and discourses in which they are …

Addiction stigma and the production of impediments to take-home naloxone uptake

R Fomiatti, A Farrugia, S Fraser, R Dwyer, J Neale… - …, 2022 - journals.sagepub.com
Opioid overdose deaths are a major health issue in Australia and around the world.
Programmes to provide opioid consumers with 'take-home'naloxone to reverse overdose …

Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia

S Nielsen, A Olsen - International Journal of Drug Policy, 2021 - Elsevier
Background There has been low community pharmacy-based naloxone supply in Australia
despite its over-the-counter status. The Behaviour Change Wheel (BCW) is a method used …

Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural …

TJ Varisco, CG Downs, KR Rathburn… - International Journal of …, 2020 - Elsevier
Background The prevalence of opioid use and misuse in the United States contributed to
48,000 opioid related deaths in 2018. Naloxone, a potent opioid reversal agent, can be …

Effectiveness and implementability of state-level naloxone access policies: expert consensus from an online modified-Delphi process

R Smart, S Grant - International Journal of Drug Policy, 2021 - Elsevier
Background Naloxone distribution, a key global strategy to prevent fatal opioid overdose,
has been a recent target of legislation in the US, but there is insufficient empirical evidence …